Prescription drug · NDA
Aphexda (Motixafortide) NDC 73441-062
Motixafortide acetate 62 mg/1.7mL · Injection, Powder, Lyophilized, For solution · Subcutaneous · Gamida Cell Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73441-062-01 | 73441006201 | 1 VIAL, GLASS in 1 CARTON (73441-062-01) / 1.7 mL in 1 VIAL, GLASSMarketed from Jun 15, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Aphexda
- Generic name (nonproprietary)
- motixafortide
- Active ingredients
- Motixafortide acetate — 62 mg/1.7mL
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Subcutaneous
- Labeler
- Gamida Cell Inc.NDC labeler code 73441
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 217159
- Marketing start
- Listing expires
- Identifiers
- Product ID 73441-062_876ecb7b-a6d5-442b-a5a1-4e24203853ccSPL ID 876ecb7b-a6d5-442b-a5a1-4e24203853ccSPL set ID e704b2db-f119-40ba-9346-9229e3281c9eRxCUI 2664901, 2664906UNII 3ZPX60DV8AUPC 0373441062013
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N473441006201followed by a unit qualifier and the quantityPackage 73441-0062-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 73441-062
- What is NDC 73441-062?
- 73441-062 is the product NDC for Aphexda (motixafortide), Motixafortide acetate 62 mg/1.7mL injection, powder, lyophilized, for solution, listed with the FDA by Gamida Cell Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Aphexda (Motixafortide).
- What is the active ingredient?
- Motixafortide acetate.
- Who is the labeler?
- Gamida Cell Inc., NDC labeler code 73441. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Aphexda?
- 1 other product NDC are listed under this name. See all Aphexda NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Aphexda products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Aphexdamotixafortide | Motixafortide acetate 62 mg/1.7mL | Injection, Powder, Lyophilized, For solutionSubcutaneous | BioLineRx USA Inc | 82737-073 | 82737-0073-01 |
Other NDCs under NDA 217159
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Aphexdamotixafortide | Motixafortide acetate 62 mg/1.7mL | Injection, Powder, Lyophilized, For solutionSubcutaneous | BioLineRx USA Inc | 82737-073 |